<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02820818</url>
  </required_header>
  <id_info>
    <org_study_id>247649</org_study_id>
    <nct_id>NCT02820818</nct_id>
  </id_info>
  <brief_title>Pulmonary Outcomes of Bronchopulmonary Dysplasia in Young Adulthood</brief_title>
  <official_title>Bronchopulmonary Dysplasia: From Neonatal Chronic Lung Disease to Early Onset Adult COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Justine's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Justine's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preterm birth alters the normal sequence of lung development with lasting respiratory&#xD;
      consequences. It is still unclear whether observed respiratory morbidities in preterm born&#xD;
      individuals reflect sequelae from a non-progressive lung disease that occurred early in life&#xD;
      or result from ongoing active disease that, if left undiagnosed and untreated, could increase&#xD;
      the risk of a COPD-like phenotype. We propose to examine micro-structural abnormalities of&#xD;
      the lung using innovative non-invasive imaging technologies in relation to pulmonary function&#xD;
      and markers of inflammation and oxidative stress in young adults born preterm.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Lung parenchymal tissue density</measure>
    <time_frame>Baseline</time_frame>
    <description>Pulmonary hydrogen protons (1H) magnetic resonance imaging (MRI) using ultra-short echo time pulse sequences will be performed to quantify signal intensity (SI) as a surrogate of parenchymal tissue density.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ventilation defect</measure>
    <time_frame>Baseline</time_frame>
    <description>Thoracic hyperpolarized 129Xe MRI to measure apparent diffusion coefficient (ADC) - subgroup of 10 participants (5 preterm, 5 control)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function - airflow limitation</measure>
    <time_frame>Baseline</time_frame>
    <description>Spirometry (FEV1/FVC) will be performed according to the American Thoracic Society guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function - lung volumes</measure>
    <time_frame>Baseline</time_frame>
    <description>Lung volumes (RV/TLC) by plethysmography will be performed according to the American Thoracic Society guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function - diffusion lung capacity</measure>
    <time_frame>Baseline</time_frame>
    <description>DLCO will be performed according to the American Thoracic Society guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function - ventilation homogeneity</measure>
    <time_frame>Baseline</time_frame>
    <description>Lung clearance index by nitrogen washout will be performed according to the American Thoracic Society guidelines</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Inflammatory and oxidative stress markers</measure>
    <time_frame>Baseline</time_frame>
    <description>Oxidative stress markers glutathione (GSH, GSSG; by capillary zone Electrophoresis) with calculation of Redox potential by the Nernst equation</description>
  </other_outcome>
  <other_outcome>
    <measure>Pneumoproteins SP-D</measure>
    <time_frame>Baseline</time_frame>
    <description>Surfactant protein D (plasma)</description>
  </other_outcome>
  <other_outcome>
    <measure>Pneumoproteins CCSP-16</measure>
    <time_frame>Baseline</time_frame>
    <description>CCSP-16 (plasma)</description>
  </other_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Premature Birth</condition>
  <condition>Obstructive Lung Disease</condition>
  <condition>Bronchopulmonary Dysplasia</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Nasal epithelial cells, whole blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        25 adults aged 20-29 born preterm (&lt;29 weeks); 25 sex and age-matched controls (friend or&#xD;
        sibling).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  20-29 years old&#xD;
&#xD;
          -  For the pre-term subject: &lt;29 weeks gestational age, with or without BPD&#xD;
&#xD;
          -  For the matched term control: â‰¥37 weeks gestational age with birth weight appropriate&#xD;
             for gestational age i.e. between the 10th and 90th percentile&#xD;
&#xD;
          -  Subject understands the study procedures and is willing to participate in the study as&#xD;
             indicated by the signature on the informed consent&#xD;
&#xD;
          -  Subject is judged to be in otherwise stable health on the basis of medical history&#xD;
&#xD;
          -  Subject is able to perform reproducible pulmonary function testing (i.e., the 3 best&#xD;
             acceptable spirograms have FEV1 values that do not vary more than 5% of the largest&#xD;
             value or more than 100 ml, whichever is greater)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient is, in the opinion of the investigator, mentally or legally incapacitated,&#xD;
             preventing informed consent from being obtained, or cannot read or understand the&#xD;
             written material&#xD;
&#xD;
          -  Patient is unable to perform spirometry or plethysmography maneuvers&#xD;
&#xD;
          -  Subject has an implanted mechanically, electrically or magnetically activated device&#xD;
             or any metal in their body which cannot be removed, including but not limited to&#xD;
             pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips,&#xD;
             bioprosthesis, artificial limb, metallic fragment or foreign body, shunt, surgical&#xD;
             staples (including clips or metallic sutures and/or ear implants)(at the discretion of&#xD;
             the MRI Technologist/3T Manager)&#xD;
&#xD;
          -  In the investigator's opinion, subject suffers from any physical, psychological or&#xD;
             other condition(s) that might prevent performance of the MRI, such as severe&#xD;
             claustrophobia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>29 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 29, 2016</study_first_submitted>
  <study_first_submitted_qc>June 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2016</study_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Justine's Hospital</investigator_affiliation>
    <investigator_full_name>Thuy Mai Luu</investigator_full_name>
    <investigator_title>Clinical associate professor of pediatrics</investigator_title>
  </responsible_party>
  <keyword>thoracic magnetic resonance imaging</keyword>
  <keyword>pulmonary function test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Bronchopulmonary Dysplasia</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

